Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product includes EXPAREL, is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL combines bupivacaine with the DepoFoam to provide postsurgical pain control with a single intraoperative infiltration.


Company Growth (employees)
Type
Public
HQ
Parsippany Troy Hills, US
Founded
2006
Size (employees)
503 (est)
Website
pacira.com
Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US

Pacira Pharmaceuticals Office Locations

Pacira Pharmaceuticals has offices in Parsippany-Troy Hills, San Diego and Jersey
Parsippany-Troy Hills, US (HQ)
5 Sylvan Way
San Diego, US
10578 Science Center Dr, Suite 125
San Diego, US
11011 N Torrey Pines Rd
Show all (3)

Pacira Pharmaceuticals Financials and Metrics

Pacira Pharmaceuticals Financials

Pacira Pharmaceuticals's revenue was reported to be $276.4 m in FY, 2016
USD

Revenue (Q2, 2017)

70.9 m

Gross profit (Q2, 2017)

47.1 m

Gross profit margin (Q2, 2017), %

66%

Net income (Q2, 2017)

(19.7 m)

EBIT (Q2, 2017)

(15.8 m)

Market capitalization (22-Dec-2017)

1.8 b

Cash (30-Jun-2017)

53.8 m
Pacira Pharmaceuticals's current market capitalization is $1.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

85.6 m197.7 m249 m276.4 m

Revenue growth, %

131%26%11%

Cost of goods sold

54.8 m77.4 m71.8 m77.4 m

Gross profit

30.8 m120.2 m177.2 m198.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

23.3 m36.7 m47.2 m52 m58.3 m59.1 m62.2 m65.5 m69.6 m68.4 m69.3 m70.9 m

Cost of goods sold

14.8 m18.1 m20 m20.4 m17.6 m18.9 m15.9 m20.3 m23.1 m43.2 m24.6 m23.8 m

Gross profit

8.5 m18.5 m27.2 m31.7 m40.7 m40.2 m46.3 m45.2 m46.6 m25.2 m44.7 m47.1 m

Gross profit Margin, %

36%51%58%61%70%68%74%69%67%37%65%66%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.5 m37.5 m57 m35.9 m

Accounts Receivable

14.6 m22.4 m25.9 m29.9 m

Inventories

15.6 m29.3 m6.1 m31.3 m

Current Assets

106.8 m214.3 m252.6 m243.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

3.4 m18.8 m108.2 m17.8 m40.9 m32.7 m30.5 m35 m25.3 m24.4 m109 m53.8 m

Accounts Receivable

9.8 m16 m20.5 m20.5 m24.5 m24.3 m25.9 m25.9 m28.7 m26.8 m27.7 m27.5 m

Inventories

15.6 m15.4 m19.2 m23.7 m36.3 m48.8 m56.1 m63.7 m60.9 m37.5 m30.3 m33.6 m

Current Assets

111.7 m98.5 m208.9 m199.2 m248.6 m258 m235.4 m448 m451 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(63.9 m)(13.7 m)1.9 m(13.7 m)

Depreciation and Amortization

5.7 m

Accounts Receivable

(10 m)(7.8 m)(3.5 m)(7.8 m)

Inventories

(3.5 m)(14 m)(32 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(52 m)(11.5 m)(16.5 m)(19.5 m)1.3 m1.3 m4.4 m(3.9 m)(11.8 m)(34 m)(19.9 m)(39.6 m)

Depreciation and Amortization

4 m2.6 m4.9 m

Accounts Receivable

(5.4 m)(1.4 m)(6 m)(5.9 m)(2.1 m)(1.9 m)(3.6 m)(46 k)(2.8 m)(910 k)2.2 m2.5 m

Inventories

(3.5 m)193 k(3.6 m)(8.1 m)(7 m)
Y, 2017

Financial Leverage

2.3 x
Show all financial metrics

Pacira Pharmaceuticals Market Value History

Pacira Pharmaceuticals's Web-traffic and Trends

Pacira Pharmaceuticals Company Life and Culture

You may also be interested in